Neumora Therap 
Welcome,         Profile    Billing    Logout  
 2 Products   1 Disease   2 Products   1 Trial   39 News 


12»
  • ||||||||||  NMRA-140 / Neumora Therap
    Journal:  Kappa opioid receptor antagonism protects working memory performance from mild stress exposure in Rhesus macaques. (Pubmed Central) -  Dec 20, 2022   
    NMRA-140 protected WM performance from the detrimental effects of FG7142-induced stress and exhibited no significant effect under non-stress conditions. Collectively, these data highlight the functional influence of the KOR system in mediating stress-induced dysfunction of executive processes and suggest that modulating KOR activity could offer therapeutic benefit in stress-related neurobehavioral disorders.
  • ||||||||||  BTRX-246040 / Neumora Therap
    Trial initiation date:  Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation (clinicaltrials.gov) -  Nov 7, 2022   
    P2,  N=112, Not yet recruiting, 
    Collectively, these data highlight the functional influence of the KOR system in mediating stress-induced dysfunction of executive processes and suggest that modulating KOR activity could offer therapeutic benefit in stress-related neurobehavioral disorders. Initiation date: Sep 2022 --> Dec 2022
  • ||||||||||  navacaprant (NMRA-140) / Neumora Therap
    Trial completion:  Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo (clinicaltrials.gov) -  Sep 10, 2022   
    P2a,  N=204, Completed, 
    Furthermore, using phEEG as a translatable biomarker, NMRA-511 was evaluated in a healthy control population and demonstrated similar changes in alpha and theta power and trends in the beta band as were observed in the marmoset. Active, not recruiting --> Completed
  • ||||||||||  NMRA-140 / Neumora Therap
    Stress, Pain and Reward Interactions and Their Clinical Relevance (713 A) -  Jul 19, 2022 - Abstract #IASP2022IASP_598;    
    However, the potential antidepressant benefits of this and other kappa antagonists such as BTRX 335140 (BlackThorn Therpeutics) are still being realized and investigated and this segment will update the status of this research. New behavioral approaches that aim to reverse fear- and stress-based brain learning will be mentioned in context, recognizing that pharmaceutical interventions may realize their greatest benefit when used to enhance the effects other interventions.
  • ||||||||||  NMRA-140 / Neumora Therap
    Journal:  Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. (Pubmed Central) -  Apr 30, 2022   
    Mice with chronic neuropathic pain also showed disrupted NREM and total sleep that was normalized by systemic administration of two structurally different KOR antagonists, norbinaltorphimine (nor-BNI) and NMRA-140, currently in phase II clinical development, or by CRISPR/Cas9 editing of PVN KOR, consistent with endogenous KOR activation disrupting sleep in chronic pain...Notably, while this mechanism is likely beneficial in the short-term, disruption of the homeostatic need for sleep over longer periods may become maladaptive resulting in sustained pain chronicity. A novel approach for treatment of chronic pain may thus result from normalization of chronic pain-related sleep disruption by KOR antagonism.
  • ||||||||||  BTRX-246040 / BlackThorn Therap
    Clinical, Journal:  Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment. (Pubmed Central) -  Feb 22, 2022   
    In a secondary analysis, we examined the association of early effects on emotional processing with later clinical outcome following treatment with the novel NOP antagonist LY2940094 versus placebo...These data suggest that emotional processing biomarkers may be sensitive to early effects of antidepressant treatment indicative of later clinical response. Further studies in this area may be useful in developing new treatments and clinical trial designs for predicting antidepressant response.
  • ||||||||||  navacaprant (NMRA-140) / Neumora Therap
    Enrollment closed:  Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo (clinicaltrials.gov) -  Jan 24, 2022   
    P2a,  N=180, Active, not recruiting, 
    Further studies in this area may be useful in developing new treatments and clinical trial designs for predicting antidepressant response. Recruiting --> Active, not recruiting
  • ||||||||||  navacaprant (NMRA-140) / Neumora Therap
    Trial completion date, Trial primary completion date:  Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo (clinicaltrials.gov) -  Oct 5, 2021   
    P2a,  N=180, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  navacaprant (NMRA-140) / Neumora Therap
    Trial completion date, Trial primary completion date:  Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo (clinicaltrials.gov) -  Feb 24, 2021   
    P2a,  N=144, Recruiting, 
    Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  aticaprant (CERC-501) / J&J, buprenorphine/samidorphan (ALKS 5461) / Alkermes, BTRX-246040 / BlackThorn Therap
    Journal:  Targeting opioid dysregulation in depression for the development of novel therapeutics. (Pubmed Central) -  Jun 29, 2020   
    Finally, putative opioid based antidepressants that are being tested in clinical trials, ALKS5461, JNJ-67953964 (formerly LY2456302 and CERC-501) and BTRX-246040 (formerly LY-2940094) will be discussed. This review will illustrate the potential therapeutic value of targeting opioid dysregulation in developing novel therapies for major depression disorder.
  • ||||||||||  BTRX-246040 / BlackThorn Therap
    Journal:  "In silico" study of the binding of two novel antagonists to the nociceptin receptor. (Pubmed Central) -  Nov 30, 2019   
    While the high selectivity for NOP of BTRX-246040 can be explained by interactions with NOP specific residues, the lack of selectivity of AT-076 could be associated to its ability to penetrate into the deep hydrophobic pocket of NOP, while retaining a conformation very similar to the one assumed by the antagonist JDTic into the K-opioid receptor. The proposed binding geometries fit better the binding pocket environment providing clues for experimental studies aimed to design selective or multifunctional opioid drugs.
  • ||||||||||  BTRX-246040 / BlackThorn Therap
    Trial completion date, Trial primary completion date:  BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations (clinicaltrials.gov) -  Mar 27, 2019   
    P2a,  N=24, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Feb 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
  • ||||||||||  BTRX-246040 / BlackThorn Therap
    Enrollment open:  BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations (clinicaltrials.gov) -  Sep 13, 2018   
    P2a,  N=32, Recruiting, 
    Trial completion date: Feb 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 Not yet recruiting --> Recruiting
  • ||||||||||  BTRX-246040 / BlackThorn Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder (clinicaltrials.gov) -  Sep 12, 2018   
    P2,  N=100, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Nov 2018
  • ||||||||||  BTRX-246040 / Neumora Therap
    Enrollment change:  A Study of LY2940094 in Major Depressive Disorder (clinicaltrials.gov) -  Feb 3, 2017   
    P1,  N=66, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Nov 2018 N=50 --> 66
  • ||||||||||  BTRX-246040 / BlackThorn Therap
    Enrollment closed:  A Study of LY2940094 in Participants With Alcohol Dependency (clinicaltrials.gov) -  Apr 24, 2014   
    P2,  N=130, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting